71 results about "Xanthine oxidase activity" patented technology

The invention discloses a tetrapeptide LILP with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicine. The amino acid sequence of the tetrapeptide LILP is Leuu-Ile-Leu-Pro, and the amino acid sequence of the tetrapeptide LILP is shown in the specification. The invention discloses that the tetrapeptide LILP has uric acid reducing activity for the first time, and uric acid generation can be reduced by reducing the activity of xanthine oxidase in the liver; uric acid discharge can be increased by reducing kidney uric acid reabsorption. The invention provides a multi-target active substance for reducing uric acid, which can be applied to preparation of medicines for preventing or treating hyperuricemia or preparation of health-care foods for assisting in reducing the level of uric acid, and has a good application prospect.

The invention discloses a tripeptide LAF with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicine. The amino acid sequence of the tripeptide LAF is Leu-Ala-Phe (Leu-Ala-Phe). The tripeptide LAF disclosed by the invention has uric acid reducing activity for the first time, and the generation of uric acid can be reduced by reducing the activity of xanthine oxidase in the liver; meanwhile, uric acid discharge is increased by reducing kidney uric acid reabsorption. The invention provides an active substance for reducing uric acid through multi-target action, and the active substance can be applied to preparation of medicines for preventing or treating hyperuricemia or preparation of foods for assisting in reducing the uric acid level, and has a good application prospect.

The invention discloses a fungus extract capable of effectively regulating uric acid metabolism and relieving inflammation as well as a preparation method and application of the fungus extract, and belongs to the technical field of deep processing of edible fungi. Schizophyllumcommuneh and poplar phellinus sporocarp are mixed and extracted, and the prepared fungus extract can effectively inhibit activity of xanthine oxidase in serum and liver of mice, reduce content of uric acid, creatinine, urea nitrogen and the like in serum and promote excretion of uric acid, creatinine, urea nitrogen and the like in urine; meanwhile, the content of inflammatory markers such as IL-6 and TNF-alpha in mouse serum can be effectively reduced, inflammatory infiltration of liver and kidney cells is relieved, and the problem that an existing edible mushroom extract is not ideal in treatment effect on hyperuricemia is solved.

The invention discloses a tripeptide LFP with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicine. The amino acid sequence of the tripeptide LFP is Leu-Phe-Pro. The tripeptide LFP disclosed by the invention has uric acid reducing activity for the first time, and the generation of uric acid can be reduced by reducing the activity of xanthine oxidase in the liver; meanwhile, uric acid discharge is increased by reducing kidney uric acid reabsorption. The invention provides a multi-target active substance for reducing uric acid, which can be applied to preparation of drugs for reducing uric acid or foods for assisting in reducing the level of uric acid, and has a good application prospect.

The invention discloses a hexapeptide TE6 with xanthine oxidase inhibitory activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptides. The amino acid sequence of the hexapeptide TE6 is TIATVE, and the hexapeptide TE6 can be prepared through a solid-phase synthesis method and an enzymolysis method. The hexapeptide TE6 is identified from a solieria cavaleriei proteolysis solution and has potential interaction with xanthine oxidase, under the concentration of 0.1 mg / mL, the xanthine oxidase inhibition rate is 44.74%, and compared with goose carnosine (the xanthine oxidase inhibition rate is 36.03%), the xanthine oxidase inhibition rate is remarkably increased (plt; 0.05), which is stronger in xanthine oxidase inhibitory activity, and can be used for preparing a preparation for inhibiting xanthine oxidase activity and relieving hyperuricemia.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus mucus BU360 with the function of improving uric acid, blood fat and blood glucose metabolism and application of the lactobacillus mucus BU360. The preservation number of the lactobacillus fermentum BU360 provided by the invention is CGMCC (China General Microbiological Culture Collection Center) No.33032. The lactobacillus fermentum BU360 provided by the invention has the advantages that the preservation number is CGMCC No.33032; the lactobacillus mucus BU360 can efficiently degrade guanosine and inosine which are precursor substances for synthesizing uric acid and directly degrade the uric acid, thalli, cell contents and metabolites of the lactobacillus mucus BU360 can inhibit the activity of xanthine oxidase and relieve HUA, and the lactobacillus mucus BU360 can directly degrade cholesterol and inhibit the activity of alpha-glucosidase and alpha-amylase, so that the lactobacillus mucus BU360 can be used for preparing the uric acid. The polypeptide has potential capability of improving blood fat and blood glucose metabolism abnormality, and assists in treatment of HUA; besides, the strain has relatively strong acid-resistant and cholate-resistant characteristics, can smoothly reach the intestinal tract of a human body, has relatively good safety on sensitivity of various antibiotics, and lays a foundation for development of related probiotic products. The lactobacillus mucus BU360 has a wide application prospect in the aspect of preparing products for relieving HUA, improving blood fat and blood glucose metabolism and the like.

The invention relates to application of bacillus coagulans BC99 in preparation of a probiotic preparation for assisting in reducing the uric acid level. The bacillus coagulans BC99 is a bacillus coagulans BC99 strain of which the preservation number is CGMCC (China General Microbiological Culture Collection Center) No. 21801, and the bacillus coagulans BC99 strain of which the preservation number is CGMCC No. 21801. The invention finds that the bacillus coagulans BC99 has a very remarkable effect in the aspect of assisting in reducing uric acid, and the effect is specifically shown as follows: the levels of serum uric acid, urea nitrogen and creatinine of a hyperuricemia rat are reduced; the xanthine oxidase activity of the hyperuricemia rats is improved; the serum inflammatory factor level of the hyperuricemia rats is regulated, and the inflammatory reaction caused by uric acid increase is inhibited; and the levels of glutamic oxalacetic transaminase and glutamic-pyruvic transaminase of high-uric-acid rats Meanwhile, the bacillus coagulans BC99 is used as a probiotic, so that the product is high in safety and not easy to generate resistance.

The invention discloses lactobacillus mucilaginosus and application thereof, and belongs to the technical field of microbial fermentation. The invention provides a lactobacillus mucus WX20 which is preserved in the Guangdong Microbial Culture Collection Center on September 12, 2024, and the preservation number of the lactobacillus mucus WX20 is GDMCC No: 65083. The lactobacillus mucus WX20 has the advantages that the lactobacillus mucus WX20 is preserved in the Guangdong Microbial Culture Collection Center on September 12, 2024; the strain obtained by screening can effectively degrade inosine and guanosine and inhibit the activity of xanthine oxidase, and has good tolerance in a simulated gastrointestinal fluid environment. When the strain is used for fermenting the leaf mustard, the fermentation period of the fermented leaf mustard can be shortened, a product prepared by utilizing the strain has the activity of degrading inosine and guanosine and inhibiting xanthine oxidase, a microbial inoculum and pickles can remarkably reduce the blood uric acid level of a mouse with hyperuricemia, and the strain has considerable application potential and high market value.

The application discloses application of total flavones of chrysanthemum morifolium ramat and metabolites thereof in preparation of uric acid-lowering or liver and kidney protecting drugs or health care products. The total flavones of chrysanthemum morifolium ramat contain various flavone compounds. In a hyperuricemia model mouse, the total flavones of chrysanthemum morifolium ramat can significantly reduce blood uric acid level, and has a significant protective effect on liver and kidney, and the effect is achieved by inhibiting the activity and expression of xanthine oxidase and adenosine deaminase in the liver, and regulating the expression of uric acid related transporters in the kidney. Meanwhile, metabolites of the total flavones of chrysanthemum morifolium ramat, luteolin-7-O-glucuronide and apigenin-7-O-glucuronide, can also play a pharmacological role in the mouse body. In vitro experiments and mouse primary hepatocytes further prove that luteolin-7-O-glucuronide and apigenin-7-O-glucuronide have an inhibiting effect on the activity and expression level of xanthine oxidase. The application widens the application range of traditional Chinese medicinal materials, and provides a new direction for development of efficient and low-toxic uric acid-lowering and anti-gout drugs or health care products.

The invention discloses a preparation method of hippocampus oil, which comprises the following steps: 1) adding dried hippocampus powder into a dichloromethane-methanol mixed solution, uniformly stirring, and extracting for 24 hours; 2) filtering the leach liquor, adding water, fully and uniformly mixing, standing for 12 hours, and collecting a lower layer organic phase; 3, the organic phase is subjected to rotary evaporation drying.The invention further discloses application of the hippocampus oil in preparation of uric acid lowering products.The hippocampus oil is rich in omega-3 polyunsaturated fatty acid (EPA and DHA), the activity of xanthine oxidase is moderately reduced, release of inflammatory factors is inhibited, and the comprehensive effect of inhibiting generation and relieving inflammation is achieved.

The invention provides a medicinal and edible tea drink composition for assisting in reducing uric acid and a preparation method thereof, and belongs to the technical field of health-care food. The medicinal and edible tea drink composition for assisting in reducing uric acid comprises corn stigma, chicory, folium mori, fructus gardeniae, radix puerariae, fructus crataegi, semen coicis, poria cocos, rhizoma polygonati, pericarpium citri reticulatae and liquorice root. Cichorium intybus and folium mori are used as monarch drugs and synergistically inhibit the activity of xanthine oxidase; corn stigma and cape jasmine are used as ministerial drugs and have the effects of forcefully inducing diuresis and reducing the blood uric The radix puerariae can improve insulin resistance, the coix seeds and the poria cocos can tonify spleen and excrete dampness, and the rhizoma polygonati can tonify spleen and tonify kidney to treat both symptoms and root causes and serve as Hawthorn, pericarpium citri reticulatae and liquorice are used for regulating the medicine property and neutralizing the bitter taste, so that the consumer experience and compliance are greatly improved. The medicinal and edible tea drink composition achieves the effect of reducing uric acid through a multi-target and multi-path synergistic effect of inhibiting generation, promoting excretion and conditioning root.

The invention discloses a preparation method of an astragalus extract with a uric acid reducing effect, and belongs to the technical field of biological medicines. The method comprises the following steps: concentrating an ethanol extract of radix astragali, extracting by using n-butyl alcohol, ethyl acetate and petroleum ether respectively, and concentrating an extract to obtain n-butyl alcohol, ethyl acetate and petroleum ether extraction parts and residual parts respectively, so as to obtain an n-butyl alcohol extract, namely the radix astragali extract for reducing uric acid. Efficacy experiments show that the normal butanol extraction part of the ethanol extract of the astragalus membranaceus can obviously reduce the serum uric acid level (SUA) of a mouse with hyperuricemia, inhibit the activity of xanthine oxidase (XOD) and effectively improve kidney injury caused by the hyperuricemia. The uric acid reducing effect of the radix astragali n-butyl alcohol extract is close to that of a clinical drug allopurinol, and the radix astragali n-butyl alcohol extract has wide development and application prospects in the aspect of relieving hyperuricemia.

The application discloses a South China Sea Decapterus maruadsi polypeptide with uric acid reducing and antioxidant activities and an application thereof, and relates to the technical field of biology. The polypeptide with high uric acid reducing activity and antioxidant activity is screened through activity prediction and molecular docking, and the amino acid sequence is FYDWWK. The polypeptide can be stably combined with the active center of xanthine oxidase, forms multiple hydrogen bonds and hydrophobic interaction, significantly inhibits the generation of uric acid, and has an in-vitro xanthine oxidase inhibition IC 50 of 3.068±0.2547 mmol / L. Meanwhile, the polypeptide has excellent DPPH free radical scavenging capacity, and an IC 50 of 5.033±0.5476 mmol / L. The polypeptide has good stability, still has high efficient inhibitory activity after simulated gastrointestinal digestion, and has oral development potential. The polypeptide is a natural marine small molecule active peptide, is safe and easy to absorb, and can be applied to the preparation of products related to uric acid reducing and / or antioxidant.

The present invention belongs to the field of biomedicine technology, and in particular relates to a sea cucumber sand spit active peptide with xanthine oxidase inhibitory activity, and its preparation method and application. The sea cucumber sand spit active peptide provided by the present invention contains at least one of FPF and WFP, has high xanthine oxidase inhibitory activity, can achieve uric acid lowering function by inhibiting xanthine oxidase activity, and can be used to prepare uric acid lowering drugs. The sea cucumber sand spit active peptide is prepared from the sand spit, a by-product of sea cucumber processing, as a raw material through bio-enzymatic hydrolysis technology under a specific process, which not only solves the problem of low utilization rate of sea cucumber processing by-products, but also reduces resource waste. The present invention provides a green and sustainable auxiliary intervention program for patients with hyperuricemia and gout, and at the same time provides an innovative way to high-value utilization of marine processing waste.

The present application provides a compound having a structure shown in Formula I, II or III or its enantiomer, diastereoisomer, racemate, stereoisomer, geometric isomer, nitroxide, metabolite or its pharmaceutically acceptable salt, ester, solvate, hydrate, isotopically labeled compound or prodrug. The non-fenofibrate 4-position ether derivative of the present application has an excellent xanthine oxidase activity inhibitory activity.

The application discloses a polypeptide with uric acid reducing activity and a preparation method and application thereof, relates to the field of bioactive peptides, and provides a preparation method of the polypeptide with uric acid reducing activity, which takes whey protein as raw material, and obtains the polypeptide with high activity through directional enzymolysis and ultrafiltration purification, and the polypeptide can reduce blood uric acid level by inhibiting xanthine oxidase activity, and the method has the advantages of high efficiency, low cost and easy implementation, can be implemented on a large scale, and is helpful to improving the utilization value of whey protein in the industry, and provides a new way for the development of functional natural anti-uric acid level abnormality or xanthine oxidase activity abnormality related disease products.

The application discloses a yak milk casein peptide with uric acid reducing activity and application thereof, and belongs to the technical field of protein peptide development. The yak milk casein peptide with clear uric acid reducing activity is prepared by taking yak milk casein as raw material, and the yak milk casein peptide can inhibit xanthine oxidase activity, reduce uric acid generation, and has good anti-inflammatory activity. The yak milk casein peptide is rich in small molecule active peptides, can be directly absorbed and utilized by the body, has excellent bioavailability, and has good application potential in improving hyperuricemia and related inflammatory damage. The application provides a new raw material source for developing hyperuricemia conditioning functional food and auxiliary intervention.

The invention discloses an application of parabacteroides dieldrii in preparation of a product for treating hyperuricemia. The activity of xanthine oxidase is inhibited through the parabacteroides dieldrii, uric acid related transporters are changed, and damaged organs are protected to play a uric acid reducing effect, so that chronic hyperuricemia is improved. In vitro, the parabacteroides dieldrii can inhibit the activity of xanthine oxidase. On the animal level, the parabacteroides dielsii can relieve liver and kidney injuries caused by hyperuricemia and can repair the injured intestinal barrier at the same time. Therefore, a design thought can be provided for an intestinal flora uric acid reducing preparation, so that a new intestinal flora target is provided for clinical treatment of hyperuricemia. According to the present invention, the activity of xanthine oxidase is inhibited in vitro, the uric acid transporter URAT1 in the kidney is reduced in vivo, the uric acid excretion transporter ABCG2 is increased, and the liver and kidney injury and the intestinal barrier damage caused by hyperuricemia are relieved so as to reduce the serum uric acid level and improve the hyperuricemia;

The processed food product has a xanthine / pyroglutamic acid ratio between the xanthine content (units: μg / g) and the pyroglutamic acid content (units: μg / g) of 0.0200 or less and a pyroglutamic acid content of 40 μg / g or greater. The processed food contains at least one component (X) selected from the group consisting of a protein having had xanthine oxidase activity and a component derived from the protein.

The invention discloses a small molecule peptide, which is derived from fugu obscurus, and the amino acid sequence of the small molecule peptide is as shown in Trp-Ala-Ala-Phe-Pro-Pro-Asp-Val-Ala-Gly-Asn, Asp-Asp-Glu-Ile-Phe-Pro-Met or Trp-Tyr-Asp-Asn-Glu-Phe-Gly. The micromolecule peptide with xanthine oxidase inhibitory activity is separated from a fugu obscurus enzymolysis product through a method of combining peptidomics and molecular docking, and experimental research verifies that the micromolecule peptide has the effect of inhibiting the xanthine oxidase activity. Therefore, the takifugu obscurus micromolecule peptide has the potential of being used as a medicine for treating the hyperuricemia and has a relatively good application prospect of preventing the hyperuricemia.

The present application belongs to the technical field of bioactive peptides, functional food and biological medicine, and particularly relates to a marine fish-derived xanthine oxidase inhibiting heptapeptide NPLVTPP and its application in reducing uric acid. The present application discloses a marine fish-derived heptapeptide NPLVTPP with xanthine oxidase inhibiting activity, and the amino acid sequence of the heptapeptide is Asn-Pro-Leu-Val-Thr-Pro-Pro. The heptapeptide can be prepared by solid-phase chemical synthesis or marine fish protein enzymatic separation and purification, can significantly inhibit xanthine oxidase activity, reduce uric acid generation, can effectively reduce serum uric acid level in a hyperuricemia animal model, and can improve high uric acid related kidney function damage. The present application also protects the application of the heptapeptide in preparing xanthine oxidase inhibitors, uric acid reducing products, products for preventing or improving hyperuricemia and kidney damage, and a medicine, food or nutritional composition containing the heptapeptide. The polypeptide sequence of the present application is clear, the target is clear, the in vivo and in vitro efficacy is clear, the source is safe, and the polypeptide can be used in the fields of functional food and biological medicine.

To provide effective and safe gout-ameliorating agents and compositions, effective and safe hepatic function-improving agents and compositions, effective and safe immunostimulating agents and compositions, effective and safe anti-aging agents and compositions, effective and safe anti-inflammatory agents and compositions, effective and safe hair tonic agents and compositions, and effective and safe antioxidative agents and compositions.SOLUTION: The invention provides a gout-ameliorating agent, hepatic function improving agent, antiaging agent, anti-inflammatory agent, hair tonic agent or antioxidative agent each comprising a Peucedanum japonicum extract.SELECTED DRAWING: None

The invention discloses a pentapeptide VE5 with xanthine oxidase inhibitory activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptides. The amino acid sequence of the pentapeptide VE5 is VSIVE, and the pentapeptide VE5 can be prepared through a solid-phase synthesis method and an enzymolysis method. The pentapeptide VE5 is identified from porphyra haitanensis proteolysis liquid and has potential interaction with xanthine oxidase, under the concentration of 0.1 mg / mL, the xanthine oxidase inhibition rate is 67.88%, and compared with goose carnosine (the xanthine oxidase inhibition rate is 36.03%), the xanthine oxidase inhibition rate is remarkably increased (plt; and the compound has higher xanthine oxidase inhibitory activity, and can be used for preparing a preparation for inhibiting xanthine oxidase activity and relieving hyperuricemia.

The application discloses a bird's nest peptide for inhibiting xanthine oxidase and application thereof, and belongs to the technical field of functional polypeptides. The amino acid sequence of the bird's nest peptide for inhibiting xanthine oxidase is WGLL, can chelate an active center of xanthine oxidase (XOD), and is helpful for inhibiting the activity of XOD in catalyzing conversion of xanthine or hypoxanthine. The application further provides a bird's nest peptide powder containing the bird's nest peptide for inhibiting xanthine oxidase. The bird's nest peptide powder can significantly reduce the rate of conversion of xanthine or hypoxanthine into uric acid catalyzed by XOD, has good uric acid reducing effect, can be applied to development of uric acid reducing products or various uric acid reducing products, and has high market value.

The present application relates to the field of biotechnology, in particular to astaxanthin and dihydroquercetin co-loaded liposome and its application in preparation of uric acid-lowering products. According to the steps of "in vitro function screening - optimal ratio determination - co-loaded liposome construction - surface coating and stabilization treatment - uric acid-lowering application verification", the obtained system is verified through physicochemical characterization, stability test and animal experiment. The results show that the co-loaded liposome can reduce the serum uric acid level of high uric acid model mice, inhibit the activity of liver xanthine oxidase, and improve the related indexes of kidney function and histopathological damage.

The application discloses a preparation method of hippocampus oil, which comprises the following steps: 1) adding hippocampus dry powder into dichloromethane-methanol mixed solution and stirring uniformly, and then leaching for 24 hours; 2) after filtering the leaching solution, adding water and mixing fully, and then standing for 12 hours, and then collecting the lower organic phase; and 3) performing rotary evaporation and drying on the organic phase. The application further discloses the use of the hippocampus oil in the preparation of a product for reducing uric acid. The hippocampus oil is rich in omega-3 polyunsaturated fatty acids (EPA and DHA), shows moderate down-regulation on xanthine oxidase activity and inhibition on the release of inflammatory factors, and achieves the comprehensive effect of 'inhibiting generation and relieving inflammation'.

The invention discloses lactobacillus fermentum HF17 capable of inhibiting xanthine oxidase activity and application of the lactobacillus fermentum HF17. The lactobacillus fermentum HF17 is lactobacillus fermentum and is preserved in the China Center for Type Culture Collection (CCTCC), and the lactobacillus fermentum HF17 is preserved in the China Center for Type Culture Collection (CCTCC). The preservation number of the strain is CCTCC (China Center For Type Culture Collection) Animal experiments show that the strain has the function of inhibiting the activity of xanthine oxidase to reduce uric acid, and lactobacillus fermentum HF17 reduces gene expression of purine metabolism related enzymes in the liver through mediation to inhibit synthesis of uric acid; according to the present invention, the gene expression of the uric acid secretion transporter in the kidney is up-regulated, the gene expression of the uric acid resorption transporter is down-regulated, and the excretion of uric acid in the mouse body is promoted so as to improve the uric acid level of the hyperuricemia mouse, improve the species richness and diversity of the intestinal flora, and improve the hyperuricemia-related metabolic disorder and other phenomena;

The present invention relates to a composite probiotic formulation for alleviating hyperuricemia and use thereof. Strains in the composite probiotic formulation for alleviating hyperuricemia comprise Bifidobacterium animalis subsp. lactis BLa80 strain with a deposit number of CGMCC No. 15410, Lacticaseibacillus rhamnosus LRa05 strain with a deposit number of CGMCC No. 1.12734, and Bifidobacterium breve BBr60 strain with a deposit number of CGMCC No. 12915. The three strains can cooperate with each other and promote each other, and have a synergistic effect in the aspect of alleviating hyperuricemia, which is specifically manifested in: alleviating the phenomenon of uric acid elevation caused by hyperuricemia, reducing xanthine oxidase activity, and lowering serum uric acid nitrogen levels.

The invention discloses oral liquid with uric acid reducing and kidney protecting effects and a preparation method and application thereof, and belongs to the technical field of biology. The oral liquid with the effects of reducing uric acid and protecting kidney comprises the following raw materials: dendrobium officinale, American ginseng, taurine and a tea extract, and auxiliary materials comprise xylitol, potassium sorbate and purified water. Dendrobium officinale and American ginseng are decocted and purified and then are mixed with other raw materials. Experiments prove that the oral liquid not only can improve weight growth, reduce blood uric acid and blood urea nitrogen levels and blood xanthine oxidase activity, but also can improve kidney indexes of hyperuricemia mice, exert an anti-oxidation effect, inhibit inflammatory response and relieve pathological damage of renal tissues, thereby exerting the effects of reducing uric acid and protecting kidneys.

The application discloses a one-pot extraction method of a Gynura divaricata compound composition and application of the Gynura divaricata compound composition in reducing uric acid, and the Gynura divaricata, sophora flower and galangal are crushed, and are weighed and uniformly mixed according to proportions; the mixture is fully extracted by using an ultrasonic-assisted ethanol extraction method, and a filtrate is obtained by filtration; the filtrate is concentrated by a rotary evaporator under reduced pressure until no alcohol taste is left, an appropriate amount of distilled water is added, and a concentrated solution is obtained; the concentrated solution is freeze-dried, and is stored in a desiccator to obtain the Gynura divaricata compound composition. The Gynura divaricata compound composition prepared by the application has the advantages of simple and rapid preparation process, low cost, high yield, good inhibition activity on xanthine oxidase, and higher inhibition rate on xanthine oxidase activity than a separately extracted and compounded composition, and is expected to be applied to preparation of a xanthine oxidase inhibiting uric acid reducing drug.